AHRP Speaks Out
Dec 12, 2005: Mental Health Screening: A PhRMA Friendly Remedy for Societal Problems. Presentation by Vera Sharav, American Public Health Association
Nov 2005: Analysis of S. 1873 – The Biodefense and Pandemic Vaccine and Drug Development Act of 2005 – Karen R. Effrem, MD
June 1-3, 2005: AMERICA’S OVERMEDICATED CHILDREN. Presented by Vera Sharav at YOUTH and MEDICINES workshop, KILEN: Consumers Institute for Medicines and Health, Stockholm, SWEDEN.
Nov 3: US Gov Pesticide Exposure Experiments: Target Children–$970 per child – Wash Post
Mar 28, 2004: Conflicts of Interest policy – New York Times
June 26, 2003: AHRP Testimonies re: Fatal ARDS lung experiment
April 5, 2003: AHRP Comments: DHHS COI Guidance for Human Subject Protection – These comments include a model self-executing conflict of interest affidavit, which AHRP has developed and is proposing for use.
January 8, 2003: “Should the EPA Accept Human Pesticide Experiments?", testimony by Vera Sharav before Committee of The National Academies of Science
October 21, 2002: AHRP Press Release Children Policy Recommendations
September 4, 2002: AHRP Replies to OHRP Response re Surrogate Consent (ARDS Study).
June 10, 2002: Memorandum in opposition to California AB 2328
May 6, 2002: "Conflicts of Interest In Clinical Trials", a presentation by Vera Hassner Sharav before the U.S. Army Medical Department and Henry M. Jackson Foundation for Advancement of Military Medicine
April 23, 2002: Congressional Testimony re: Protecting Children in Research
March 11, 2002: AHRP Challenges Effort to Redifine Who is a Human Subject
October 29, 2001
Conflicts of Interest undermine Safety for Human Subjects
October 1, 2001
AHRP Infomail re: Maryland Court of Appeals landmark decision on August 16, 2001.
August 20, 2001
A landmark decision by Maryland’s highest court, the Court of Appeals of Maryland, is a victory for the human rights of children.
August 20b, 2001
The Scientist News reports on AHRP as New Advocacy Group to Police Human Research
August 6, 2001
Comments on Docket #00N-0074 April 24, 2001 Interim Rule: "Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products, by Vera Hassner Sharav, John H. Noble, Jr., Ph.D and Howard Fishman, MEd, MSW
July 25, 2001
Specific Comment to National Human Research Protections Advisory Committee (NHRPAC) on FDA’s Decision
Comments Submitted to the Office of Human Research Protection (OHRP) by Vera Hassner Sharav and Marie M. Cassidy, Ph.D, D.Sc.